Xenetic Biosciences | 10-Q: FY2025 Q3 Revenue: USD 1.027 M

Revenue: As of FY2025 Q3, the actual value is USD 1.027 M.

EPS: As of FY2025 Q3, the actual value is USD -0.33, beating the estimate of USD -0.49.

EBIT: As of FY2025 Q3, the actual value is USD -575.52 K.

Revenue

• Royalty revenue for the three months ended September 30, 2025 was $1,026,957, an increase of 67.2% compared to $614,243 for the same period in 2024.
• For the nine months ended September 30, 2025, royalty revenue was $2,210,115, up 19.4% from $1,851,464 in the same period in 2024.

Operating Costs and Expenses

• Research and development expenses for the three months ended September 30, 2025 were $756,482, a 105.6% increase from $367,985 in the same period in 2024.
• General and administrative expenses for the three months ended September 30, 2025 were $815,209, up 9.3% from $745,731 in the same period in 2024.
• Total operating costs and expenses for the nine months ended September 30, 2025 were $4,421,670, a decrease of 10.8% from $4,956,747 in the same period in 2024.

Net Loss

• Net loss for the three months ended September 30, 2025 was $509,940, an increase of 16.8% compared to $436,671 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025 was $2,101,784, a decrease of 27.7% from $2,905,754 in the same period in 2024.

Cash Flow

• Cash flows used in operating activities for the nine months ended September 30, 2025 totaled approximately $2,043,969, compared to $2,143,486 for the same period in 2024.

Future Outlook and Strategy

• The company is considering strategic alternatives to maximize shareholder value, including potential sales or business combinations, but no definitive timetable or assurance of a transaction is provided.
• Xenetic Biosciences, Inc. remains committed to advancing its DNase technology and anticipates needing additional capital in the long-term to pursue business initiatives.